AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19967490 — intervention group
Group type: COMPARATOR
Intervention: UFT (2 x 100‐mg capsules) and leucovorin (1 x 25‐mg tablet) taken after fasting
Number of subjects: 12
Study 16919112 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (group A)
Number of subjects: 40
Study 16919112 — intervention group
Group type: COMPARATOR
Intervention: Cold scalpel (group B)
Number of subjects: 40
Study 15245618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 5 years
Number of subjects: 194
Study 15245618 — intervention group
Group type: COMPARATOR
Intervention: High-dose oral medroxyprogesterone acetate (MPA) 1 g orally for 9 months
Number of subjects: 194
Study 15245618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 194
Study 15245618 — intervention group
Group type: COMPARATOR
Intervention: MPA
Number of subjects: 194
Study 11374600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation
Number of subjects: 15
Study 11374600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine inhalation
Number of subjects: 15
Study 11374600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyclonine inhalation
Number of subjects: 15
Study 11374600 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 15
Study 9039247 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (38.0 (6.4) mg, pH = 9)
Number of subjects: 14
Study 9039247 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (0.9% NaCl, pH = 9)
Number of subjects: 14
Study 9039247 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide
Number of subjects: 14
Study 9039247 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 14
Study 8381758 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (100 micrograms/kg iv)
Number of subjects: 20
Study 8381758 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (80 micrograms/kg iv)
Number of subjects: 20
Study 8381758 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg iv)
Number of subjects: 20
Study 3121021 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram stained conjunctival smear
Number of subjects: 90
Study 3121021 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol eye ointment
Number of subjects: 90
Study 3121021 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture and microimmunofluorescence test
Number of subjects: 90
Study 31098985 — intervention group
Group type: COMPARATOR
Intervention: no information
Number of subjects: 488
Study 31098985 — intervention group
Group type: COMPARATOR
Intervention: neutral information
Number of subjects: 488
Study 31098985 — intervention group
Group type: EXPERIMENTAL
Intervention: eating disorders emphasis
Number of subjects: 488
Study 31098985 — intervention group
Group type: EXPERIMENTAL
Intervention: obesity emphasis
Number of subjects: 488
Study 29565949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) applied for 8 minutes
Number of subjects: 36
Study 29565949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) applied for 2, 4, or 6 minutes
Number of subjects: 36
Study 29565949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) applied for 2, 4, 6, or 8 minutes
Number of subjects: 36
Study 29565949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRF intervention)
Number of subjects: 36
Study 27545102 — intervention group
Group type: EXPERIMENTAL
Intervention: External stent
Number of subjects: 93
Study 27545102 — intervention group
Group type: COMPARATOR
Intervention: Double J stent
Number of subjects: 93
Study 24831918 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0
Study 24831918 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 22373886 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention (physical activity program, nutrition lessons, media use, sleep)
Number of subjects: 652
Study 22373886 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention
Number of subjects: 652
Study 20709444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 72
Study 20709444 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator suburethral tape (TVT-O)
Number of subjects: 72
Study 20709444 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (TVT and TVT-O)
Number of subjects: 72
Study 19157042 — intervention group
Group type: EXPERIMENTAL
Intervention: 5th grade keepin' it REAL (kiR) curriculum
Number of subjects: 1566
Study 19157042 — intervention group
Group type: COMPARATOR
Intervention: Control condition (pre-existing substance use prevention programming)
Number of subjects: 1566
Study 15748783 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 35
Study 15748783 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol/Progesterone
Number of subjects: 35
Study 15748783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12221342 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Number of subjects: 64
Study 12221342 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner management
Number of subjects: 64
Study 9707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 0
Study 9707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg
Number of subjects: 0
Study 9707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg
Number of subjects: 0
Study 9707465 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg
Number of subjects: 0
Study 9707465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7977431 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and health promotion program (PROPATH)
Number of subjects: 290
Study 7977431 — intervention group
Group type: COMPARATOR
Intervention: Control group (received only questionnaires)
Number of subjects: 290
Study 2607948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle training group
Number of subjects: 32
Study 2607948 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTsub group (70-85% of RM)
Number of subjects: 32
Study 2607948 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTmax group (maximal repetitions possible)
Number of subjects: 32
Study 2607948 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 32
Study 29361468 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant plus adjuvant dabrafenib and trametinib (8 weeks of neoadjuvant oral dabrafenib 150 mg twice per day and oral trametinib 2 mg per day followed by surgery, then up to 44 weeks of adjuvant dabrafenib plus trametinib starting 1 week after surgery for a total of 52 weeks of treatment)
Number of subjects: 21
Study 29361468 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (upfront surgery and consideration for adjuvant therapy)
Number of subjects: 21
Study 27491453 — intervention group
Group type: EXPERIMENTAL
Intervention: DTL microfiber electrode
Number of subjects: 30
Study 27491453 — intervention group
Group type: COMPARATOR
Intervention: Neuroline skin electrode
Number of subjects: 30
Study 24099723 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in dietary trans fat intake
Number of subjects: 400
Study 22250644 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight‐mediated PDT with 1½ h exposure
Number of subjects: 145
Study 22250644 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight‐mediated PDT with 2½ h exposure
Number of subjects: 145
Study 22250644 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight‐mediated PDT for grade II lesions
Number of subjects: 145
Study 22250644 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight‐mediated PDT for grade III lesions
Number of subjects: 145
Study 20471224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use disorders (CUD)
Number of subjects: 100
Study 20471224 — intervention group
Group type: EXPERIMENTAL
Intervention: CUD subjects
Number of subjects: 100
Study 20471224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 100
Study 20471224 — intervention group
Group type: COMPARATOR
Intervention: Non-substance abusing subjects
Number of subjects: 100
Study 18567276 — intervention group
Group type: EXPERIMENTAL
Intervention: AmnioStat‐FLM test (initial analysis)
Number of subjects: 200
Study 18567276 — intervention group
Group type: EXPERIMENTAL
Intervention: AmnioStat‐FLM test (post-freeze-thaw analysis)
Number of subjects: 200
Study 15839295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated intervention for 12 weeks by telephone
Number of subjects: 25
Study 15839295 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 15839295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated intervention
Number of subjects: 25
Study 12432176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 12
Study 12432176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 12
Study 12432176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 12
Study 12432176 — intervention group
Group type: COMPARATOR
Intervention: Control (High-carbohydrate vs High-protein and High-fat)
Number of subjects: 12
Study 10857943 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200-5,000 microg/day subcutaneously)
Number of subjects: 23
Study 10857943 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes management (control group)
Number of subjects: 23
Study 10857943 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 23
Study 8931419 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate gel 1 g b.i.d. for 14 days
Number of subjects: 107
Study 8931419 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 1563120 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (50 mg/m2/day)
Number of subjects: 8
Study 1563120 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study 1563120 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (for boys with initial growth velocity below mean of healthy control group)
Number of subjects: 8
Study 1563120 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (for boys with initial growth velocity normal)
Number of subjects: 8
Study 3161613 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of MPA daily (Group 1)
Number of subjects: 41
Study 3161613 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of MPA (Group 2)
Number of subjects: 41
Study 3161613 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of MPA (Group 3)
Number of subjects: 41
Study 3161613 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 postmenopausal breast cancer patients without treatment)
Number of subjects: 41
Study 31205120 — intervention group
Group type: EXPERIMENTAL
Intervention: Left high-frequency rTMS
Number of subjects: 25
Study 31205120 — intervention group
Group type: COMPARATOR
Intervention: Right high-frequency rTMS
Number of subjects: 25
Study 30265057 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Network Counseling‐txt (PNC‐txt)
Number of subjects: 96
Study 30265057 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control condition
Number of subjects: 96
Study 26283739 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (titrated to a maximum dose of 1.8 mg)
Number of subjects: 24
Study 26283739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24742660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1098
Study 24742660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 1098
Study 24742660 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 1098
Study 21864479 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel paediatric self-inflating bags (NPB)
Number of subjects: 73
Study 21864479 — intervention group
Group type: COMPARATOR
Intervention: Conventional paediatric self-inflating bags (CPB)
Number of subjects: 73
Study 20841339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 34
Study 20841339 — intervention group
Group type: COMPARATOR
Intervention: Usual controlled care
Number of subjects: 34
Study 17548781 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (1 to 20 mg/d)
Number of subjects: 1267
Study 17548781 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1267
Study 16116358 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention including local priority setting, quality improvement plan development, implementation, and monitoring.
Number of subjects: 280
Study 11699044 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART) including AZT or D4T plus 3TC and either IND, NELF, RITV, or SAQ at standard dosage
Number of subjects: 17
Study 11699044 — intervention group
Group type: COMPARATOR
Intervention: Control group of 42 healthy individuals (28 men and 14 women; 24‐ to 82‐years‐old)
Number of subjects: 17
Study 11699044 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 17
Study 9156035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg)
Number of subjects: 8
Study 9156035 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 7956563 — intervention group
Group type: EXPERIMENTAL
Intervention: SVATE (15 cases)
Number of subjects: 52
Study 7956563 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (15 cases)
Number of subjects: 52
Study 7956563 — intervention group
Group type: COMPARATOR
Intervention: Control (22 cases)
Number of subjects: 52
Study 3675893 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper prosthesis treatment group
Number of subjects: 60
Study 3675893 — intervention group
Group type: COMPARATOR
Intervention: Control group (no paper prosthesis)
Number of subjects: 60
Study 2379771 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cholecystokinin‐8 infusion at rates of 21, 42, and 84 pmol/min
Number of subjects: 18
Study 2379771 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study 4594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved method of peroperative intermittent calf compression
Number of subjects: 99
Study 30573142 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1635
Study 30573142 — intervention group
Group type: COMPARATOR
Intervention: Health education (Control)
Number of subjects: 1635
Study 28755971 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of H. sabdariffa L. (1000ml)
Number of subjects: 130
Study 28755971 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of H. sabdariffa L. (1500ml)
Number of subjects: 130
Study 28755971 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of H. sabdariffa L. (2000ml)
Number of subjects: 130
Study 28755971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablet (200mg)
Number of subjects: 130
Study 28755971 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 130
Study 26068449 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based interactive self-management education course (2-day duration)
Number of subjects: 0
Study 26068449 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 23080291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 20mg/kg/day
Number of subjects: 95
Study 23080291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 21798494 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDP >18 mm Hg
Number of subjects: 2797
Study 21798494 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDP ≥24 mm Hg
Number of subjects: 2797
Study 21798494 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased LVEDP
Number of subjects: 2797
Study 19380385 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week weight loss programme
Number of subjects: 52
Study 16763802 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits with geriatric training for health visitors and general practitioners
Number of subjects: 4034
Study 16763802 — intervention group
Group type: COMPARATOR
Intervention: Preventive home visits as usual (control group)
Number of subjects: 4034
Study 15003079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol, 2.5 mg t.i.d.
Number of subjects: 42
Study 15003079 — intervention group
Group type: COMPARATOR
Intervention: Sham augmentation (Control)
Number of subjects: 42
Study 11716199 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Easyhaler 800 microg day(‐1)
Number of subjects: 15
Study 11716199 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Easyhaler 1600 microg day(‐1)
Number of subjects: 15
Study 11716199 — intervention group
Group type: COMPARATOR
Intervention: Placebo Easyhaler plus Pulmicort Turbuhaler 800 microg day(‐1)
Number of subjects: 15
Study 11716199 — intervention group
Group type: COMPARATOR
Intervention: Placebo Easyhaler plus Pulmicort Turbuhaler 1600 microg day(‐1)
Number of subjects: 15
Study 11716199 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Easyhaler and Turbuhaler (both doses)
Number of subjects: 15
Study 11716199 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 15
Study 9523477 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR surface antigens
Number of subjects: 18
Study 9523477 — intervention group
Group type: COMPARATOR
Intervention: CD4, CD8, CD56, CD16 surface antigens
Number of subjects: 18
Study 9523477 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 surface antigens
Number of subjects: 18
Study 9523477 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 to CD8 ratio
Number of subjects: 18
Study 9523477 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cells forming active and total rosettes
Number of subjects: 18
Study 9523477 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cells reaction to theophylline
Number of subjects: 18
Study 7955272 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde warm blood cardioplegia
Number of subjects: 75
Study 7955272 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cold crystalloid cardioplegia
Number of subjects: 75
Study 2440125 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hour infusion of iloprost
Number of subjects: 19
Study 2440125 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 19
Study 29921250 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 15
Study 29921250 — intervention group
Group type: COMPARATOR
Intervention: Sham taping (ST)
Number of subjects: 15
Study 28968227 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective exercise strategy
Number of subjects: 60
Study 28968227 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 60
Study 26066651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive handwashing promotion (soap and daily handwashing promotion)
Number of subjects: 377
Study 26066651 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 377
Study 23044653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 240
Study 23044653 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 240
Study 23044653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 240
Study 23044653 — intervention group
Group type: COMPARATOR
Intervention: Control (no anesthesia)
Number of subjects: 240
Study 21278400 — intervention group
Group type: EXPERIMENTAL
Intervention: C-POL intervention
Number of subjects: 3912
Study 21278400 — intervention group
Group type: COMPARATOR
Intervention: Standard-care control
Number of subjects: 3912
Study 19169852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin after endovascular coiling
Number of subjects: 315
Study 19169852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin after neurosurgical clipping
Number of subjects: 315
Study 19169852 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium after endovascular coiling
Number of subjects: 315
Study 19169852 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium after neurosurgical clipping
Number of subjects: 315
Study 16267074 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective CPAP therapy
Number of subjects: 31
Study 16267074 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 31
Study 16267074 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 31
Study 15363431 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation only
Number of subjects: 72
Study 15363431 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation with physical modalities (PM)
Number of subjects: 72
Study 15363431 — intervention group
Group type: COMPARATOR
Intervention: High-velocity low-amplitude spinal manipulation
Number of subjects: 72
Study 11245648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0
Study 11245648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9394693 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Zn/d (zinc supplementation)
Number of subjects: 98
Study 9394693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 7954566 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive group (HT)
Number of subjects: 90
Study 2431864 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg oral dose of cocaine hydrochloride
Number of subjects: 12
Study 2431864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12